<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04703465</url>
  </required_header>
  <id_info>
    <org_study_id>In the application</org_study_id>
    <nct_id>NCT04703465</nct_id>
  </id_info>
  <brief_title>Tenofovir Alafenamide for HBV Prophylaxis in HBV(-) Liver Transplant Recipients With HBcAb+ Donors</brief_title>
  <official_title>Effectiveness and Safety of Tenofovir Alafenamide for HBV Prophylaxis in HBV Negative Recipients Received Orthotopic Liver Transplant With HBcAb+ Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Liver transplantation is currently the only effective way to treat end-stage liver&#xD;
      disease.The shortage of donor liver is still the major problem. Incidence of HBcAb+ varies&#xD;
      between different regions. The HBcAb positive rate could be as high as 52% in China.HBcAb&#xD;
      positive donor liver may enlarge donor pool and thus save ESLD patients. However, the use of&#xD;
      HBcAb positive donor liver may induce HBV infection in hepatitis B negative recipient after&#xD;
      liver transplantation. Tenofovir alafenamide (TAF) has better stability in plasma and higher&#xD;
      liver targeting property in comparison with tenofovir (TDF), with an extra amide bond, which&#xD;
      allows strong antiviral effect with much less doses and reducing the renal and bone injury.&#xD;
      Our study intends to evaluate the efficacy and safety of HBV prophylaxis treatment of TAF in&#xD;
      HBV negative patients after receiving HBcAb positive donor livers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We intent to enroll 30 patients who are HBV negative but received HBcAb+ liver. Antiviral&#xD;
      treatment with TAF(25mg/d,oral) will be started on the first day after liver transplantation.&#xD;
      Post-operative HBV infection is defined with positive HBV marker (HBsAg) and/or positive HBV&#xD;
      DNA after liver transplantation. Primary outcome will be evaluated at 48 weeks. All the&#xD;
      patients will be followed up for another at least 1 year to evaluate the long term efficacy&#xD;
      and safety of TAF.&#xD;
&#xD;
      The primary endpoint is to calculate de novo HBV infection after liver transplantation when&#xD;
      treating with TAF. Secondary endpoint is to evaluate the renal safety of TAF after liver&#xD;
      transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>De novo HBV infected rate after liver transplantation at 48 weeks</measure>
    <time_frame>48 weeks</time_frame>
    <description>Primary outcome is to calculate de novo HBV infection after liver transplantation when treating with TAF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>48 weeks Renal safety of TAF after liver transplantation.</measure>
    <time_frame>48 weeks</time_frame>
    <description>Secondary outcome is to evaluate changes in renal function (Serum Creatinine, eGFR, β2-MG: Cr, RBP:Cr) at 48 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>96 weeks Renal safety of TAF after liver transplantation.</measure>
    <time_frame>96 weeks</time_frame>
    <description>Secondary outcome is to evaluate changes in renal function (Serum Creatinine, eGFR, β2-MG: Cr, RBP:Cr) at 96 weeks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>HBV</condition>
  <condition>Liver Transplant Disorder</condition>
  <arm_group>
    <arm_group_label>tenofovir alafenamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tenofovir alafenamide 25mg daily for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Alafenamide 25 MG</intervention_name>
    <description>Tenofovir Alafenamide 25mg for 48 weeks will be delivered</description>
    <arm_group_label>tenofovir alafenamide</arm_group_label>
    <other_name>Vemlidy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with written informed consent.&#xD;
&#xD;
          2. Age ≥12 years old&#xD;
&#xD;
          3. HBV negative recipients (HBV DNA undetectable and HBsAg negative) receiving HBsAg-,&#xD;
             HBcAb+ donor liver&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients underwent liver re-transplantation&#xD;
&#xD;
          2. CKD (CrCl&lt;30 ml/min by MDRD formula)&#xD;
&#xD;
          3. HBV/HCV-related OLT&#xD;
&#xD;
          4. Other solid organs transplant recipients&#xD;
&#xD;
          5. HIV coinfection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiang Xia, MD., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhifeng Xi, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiang Xia, MD., Ph.D.</last_name>
    <phone>+8602168383775</phone>
    <email>xiaqiang@shsmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhifeng Xi, MD.</last_name>
    <phone>+8602168383715</phone>
    <email>xizhifeng@renji.com</email>
  </overall_contact_backup>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 8, 2021</last_update_submitted>
  <last_update_submitted_qc>January 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

